Last reviewed · How we verify
Ethiodized Oil-based emulsion
Ethiodized oil-based emulsion acts as a radiopaque contrast agent and immunomodulatory agent that enhances imaging and may stimulate immune responses against cancer cells.
Ethiodized oil-based emulsion acts as a radiopaque contrast agent and immunomodulatory agent that enhances imaging and may stimulate immune responses against cancer cells. Used for Hepatocellular carcinoma (transarterial chemoembolization or immunotherapy).
At a glance
| Generic name | Ethiodized Oil-based emulsion |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Drug class | Radiopaque contrast agent / Immunomodulatory emulsion |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Ethiodized oil is an iodinated poppy seed oil that provides radiographic contrast for imaging procedures. When formulated as an emulsion, it can be used as a carrier for chemotherapy or as an immunotherapeutic agent. The iodine content provides radiopacity for visualization, while the oil-based formulation may enhance cellular uptake and trigger immune-mediated antitumor effects through activation of innate immunity.
Approved indications
- Hepatocellular carcinoma (transarterial chemoembolization or immunotherapy)
Common side effects
- Hepatic toxicity
- Abdominal pain
- Fever
- Nausea
Key clinical trials
- Comparison of SBRT and SIRT With Combination IO for Locally-advanced, Unresectable HCCs (BIIRTH) (PHASE2, PHASE3)
- TACE Combined With Anti-PD-1 Antibody in Patients With Advanced Hepatocellular Carcinoma: Study on Efficacy and Immune Microenvironment
- Emulsion Versus Suspension in Chemoembolization for Hepatocellular Carcinoma (NA)
- Effect of Genicular Arteries Embolization in Symptomatic Knee Osteoarthritis LipioJoint-2 (PHASE3)
- Lipiodol-TACE With Idarubicin Based On a Specific Emulsion Ratio for Hepatocellular Carcinoma
- DEB-TACE vs. cTACE as Conversion Therapy for Unresectable Large HCC (NA)
- TACE With Dicycloplatin(TP21) in Unresectable HCC (PHASE3)
- Idarubicin vs. Epirubicin TACE in the Treatment of Hepatocellular Carcinoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ethiodized Oil-based emulsion CI brief — competitive landscape report
- Ethiodized Oil-based emulsion updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI